Press Releases April 30, 2026 04:05 PM

Cibus to Report First Quarter 2026 Financial Results on May 14, 2026 After the Market Close and Host Conference Call

Cibus to announce Q1 2026 financial results with conference call scheduled for May 14, 2026

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
CBUS

Cibus, Inc., an agricultural technology company specializing in gene editing plant traits, will report its first quarter 2026 financial results on May 14, 2026, followed by a conference call. The company focuses on developing traits to improve crop productivity, yield, and sustainability, licensing these traits to seed companies.

Cibus to Report First Quarter 2026 Financial Results on May 14, 2026 After the Market Close and Host Conference Call
CBUS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Cibus will report Q1 2026 financial results on May 14, 2026, after market close.
  • A conference call and webcast will discuss financial results and company updates.
  • Cibus develops gene-edited plant traits and licenses them, focusing on improving global row crop productivity and sustainability.

SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report first quarter 2026 financial results on Thursday, May 14, 2026. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.

Title: Cibus, Inc. First Quarter 2026 Results Conference Call
Event Date: Thursday, May 14, 2026        
Time: 4:30 p.m. ET        
Participant Numbers: +1-800-274-8461 (U.S.), +1-203-518-9814 (International)
The conference ID “CIBUS” or 24287 will be required for entry
Event Link: https://investor.cibus.com/events

For interested individuals unable to join the conference call, a dial-in replay of the call will be available through Thursday, May 28, 2026, and can be accessed by dialing +1-844-512-2921 (U.S.), +1-412-317-6671 (International) and entering replay passcode: 11161515.

A live audio webcast of the call, along with accompanying slides, will be available under "News & Events” in the Investor section of the Company's website, investor.cibus.com. An archived webcast will be available on the Company's website for 90 days after the event.

About Cibus

Cibus is a leader in developing traits (characteristics) that address critical productivity, yield and sustainability challenges. Cibus’ proprietary high-throughput gene editing technologies drive its long-term focus on productivity traits for farmers for the major global row crops. Cibus is not a seed company. It is a technology company that uses its gene editing technologies to develop plant traits at a fraction of the time and cost of conventional breeding and to license them to customers in exchange for royalties.

Cibus Contacts:

Investor Relations
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com

Media Relations
Colin Sanford
colin@bioscribe.com
203-918-4347


Risks

  • Reliance on licensing revenue exposes Cibus to market demand variability for its traits.
  • The agricultural technology sector faces regulatory and adoption risks regarding gene editing techniques.
  • Financial performance disclosed may be impacted by competition in biotechnology and seed trait development sectors.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026